Special Issue "Development of Pneumococcal Vaccines for the World"
Deadline for manuscript submissions: 30 June 2020.
Interests: mucosal immunology; immunoregulation (in autoimmune diseases, allergic diseases and infections); interaction between gut microbiota and the immune system; vaccination
Special Issues and Collections in MDPI journals
Ninety years ago, Oswald Avery made a breakthrough discovery when he coupled proteins to bacterial polysaccharides and found that the resulting conjugate possessed improved immunogenicity and even induced immunological memory. After a lag period of over half a century, his principles have been applied in the design of a whole new category of pneumococcal vaccines: The pneumococcal conjugate vaccines. These vaccines, directed against the 7–13 most prevalent pneumococcal serotypes, are effective in the prevention of both invasive as well as mucosal pneumococcal infections in children. Despite this success, and despite antibiotic treatment options, the burden of pneumococcal pneumonia in terms of morbidity and mortality remains high, both for children and the elderly. The issues to be addressed in the field of vaccine development are serotype coverage, serotype replacement, geographical distribution of serotypes, nature of the vaccines (polysaccharide or protein based), as well as (economical) affordability. We therefore invite all clinical and biomedical researchers, whether from this field or coming from a clinical, public health, or manufacturing background, to submit their work to be considered for publication in this Special Issue.
Prof. Dr. Ger Rijkers
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pathogens is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1400 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- pneumococcal vaccines
- polysaccharide conjugates
- global epidemiology
The below list represents only planned manuscripts. Some of these manuscripts have not been received by the Editorial Office yet. Papers submitted to MDPI journals are subject to peer-review.
Estimating the clinical and economic impact of switching from the 13-valent pneumococcal conjugate vaccine (PCV13) to the 10-valent pneumococcal conjugate vaccine (PCV10) in Italy